H Zhao1, J A Jung, D E Briles, H Kita, C Tsigrelis, Y J Juhn. 1. Division of Community Pediatric and Adolescent Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA.
Abstract
PURPOSE: We previously reported that asthmatics had lower anti-serotype-specific pneumococcal polysaccharide antibody levels than non-asthmatics, and the T-helper 2 (Th2) immune profile was associated with suboptimal pneumococcal polysaccharide antibody. Our objective was to determine the influence of asthma status on anti-pneumococcal protein antigen antibody levels. METHODS: We conducted a cross-sectional study, which enrolled 16 children and adults with asthma and 14 subjects without asthma. Asthma was ascertained by predetermined criteria. Serum IgG antibody levels to pneumococcal surface protein A (PspA), pneumococcal surface protein C (PspC), pneumococcal choline-binding protein A (PcpA), and pneumolysin (PLY) were measured by enzyme-linked immunosorbent assays (ELISA). These antibody levels were compared between asthmatics and non-asthmatics. The Th2 immune profile was determined by IL-5 secretion from PBMCs cultured with house dust mite (HDM) and staphylococcal enterotoxin B (SEB) at day 7. The correlation between the anti-pneumococcal antibody levels and the Th2-HDM and SEB-responsive immune profile was assessed. RESULTS: Of the 30 subjects, 16 (53%) were male and the median age was 26 years. There were no significant differences in anti-PspA, anti-PspC, anti-PcpA, and anti-PLY antibody levels between asthmatics and non-asthmatics. The Th2 immune profile was inversely correlated with the anti-PspC antibody levels (r = -0.53, p = 0.003). This correlation was significantly modified by asthma status (r = -0.74, p = 0.001 for asthmatics vs. r = -0.06, p = 0.83 for non-asthmatics). Other pneumococcal protein antibodies were not correlated with the Th2 immune profile. CONCLUSION: No significant differences in the anti-pneumococcal protein antigen antibody levels between asthmatics and non-asthmatics were found. Asthma status is an important effect modifier determining the negative influence of the Th2 immune profile on anti-PspC antibody levels.
PURPOSE: We previously reported that asthmatics had lower anti-serotype-specific pneumococcalpolysaccharide antibody levels than non-asthmatics, and the T-helper 2 (Th2) immune profile was associated with suboptimal pneumococcalpolysaccharide antibody. Our objective was to determine the influence of asthma status on anti-pneumococcal protein antigen antibody levels. METHODS: We conducted a cross-sectional study, which enrolled 16 children and adults with asthma and 14 subjects without asthma. Asthma was ascertained by predetermined criteria. Serum IgG antibody levels to pneumococcal surface protein A (PspA), pneumococcal surface protein C (PspC), pneumococcalcholine-binding protein A (PcpA), and pneumolysin (PLY) were measured by enzyme-linked immunosorbent assays (ELISA). These antibody levels were compared between asthmatics and non-asthmatics. The Th2 immune profile was determined by IL-5 secretion from PBMCs cultured with house dust mite (HDM) and staphylococcal enterotoxin B (SEB) at day 7. The correlation between the anti-pneumococcal antibody levels and the Th2-HDM and SEB-responsive immune profile was assessed. RESULTS: Of the 30 subjects, 16 (53%) were male and the median age was 26 years. There were no significant differences in anti-PspA, anti-PspC, anti-PcpA, and anti-PLY antibody levels between asthmatics and non-asthmatics. The Th2 immune profile was inversely correlated with the anti-PspC antibody levels (r = -0.53, p = 0.003). This correlation was significantly modified by asthma status (r = -0.74, p = 0.001 for asthmatics vs. r = -0.06, p = 0.83 for non-asthmatics). Other pneumococcal protein antibodies were not correlated with the Th2 immune profile. CONCLUSION: No significant differences in the anti-pneumococcal protein antigen antibody levels between asthmatics and non-asthmatics were found. Asthma status is an important effect modifier determining the negative influence of the Th2 immune profile on anti-PspC antibody levels.
Authors: D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead Journal: Infect Immun Date: 2000-02 Impact factor: 3.441
Authors: K A Robinson; W Baughman; G Rothrock; N L Barrett; M Pass; C Lexau; B Damaske; K Stefonek; B Barnes; J Patterson; E R Zell; A Schuchat; C G Whitney Journal: JAMA Date: 2001-04-04 Impact factor: 56.272
Authors: D E Briles; S Hollingshead; A Brooks-Walter; G S Nabors; L Ferguson; M Schilling; S Gravenstein; P Braun; J King; A Swift Journal: Vaccine Date: 2000-02-25 Impact factor: 3.641
Authors: Sheila M G Marra; Rosiane O Borges; Ronaldo Alves; Deise A O Silva; Ernesto A Taketomi; Gesmar R S Segundo Journal: Am J Rhinol Allergy Date: 2011 Sep-Oct Impact factor: 2.467
Authors: Belinda J Hales; Lee Ying Chai; Claire E Elliot; Leigh J Pearce; Guicheng Zhang; Tatjana K Heinrich; Wendy-Anne Smith; Merci M Kusel; Patrick G Holt; Peter D Sly; Wayne R Thomas Journal: Thorax Date: 2011-11-21 Impact factor: 9.139
Authors: D Bogaert; M N Engelen; A J Timmers-Reker; K P Elzenaar; P G Peerbooms; R A Coutinho; R de Groot; P W Hermans Journal: J Clin Microbiol Date: 2001-09 Impact factor: 5.948
Authors: M C Vela Coral; N Fonseca; E Castañeda; J L Di Fabio; S K Hollingshead; D E Briles Journal: Emerg Infect Dis Date: 2001 Sep-Oct Impact factor: 6.883